{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:26:26Z","timestamp":1791851186164,"version":"4.3.4"},"reference-count":29,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2009,12,28]],"date-time":"2009-12-28T00:00:00Z","timestamp":1261958400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis &amp; Rheumatism"],"published-print":{"date-parts":[[2010,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>To compare tumor necrosis factor \u03b1 inhibitors directly regarding the rates of treatment response, remission, and the drug survival rate in patients with rheumatoid arthritis (RA), and to identify clinical prognostic factors for response.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The nationwide DANBIO registry collects data on rheumatology patients receiving routine care. For the present study, we included patients from DANBIO who had RA (n = 2,326) in whom the first biologic treatment was initiated (29% received adalimumab, 22% received etanercept, and 49% received infliximab). Baseline predictors of treatment response were identified. The odds ratios (ORs) for clinical responses and remission and hazard ratios (HRs) for drug withdrawal were calculated, corrected for age, disease duration, the Disease Activity Score in 28 joints (DAS28), seropositivity, concomitant methotrexate and prednisolone, number of previous disease\u2010modifying drugs, center, and functional status (Health Assessment Questionnaire score).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Seventy percent improvement according to the American College of Rheumatology criteria (an ACR70 response) was achieved in 19% of patients after 6 months. Older age, concomitant prednisolone treatment, and low functional status at baseline were negative predictors. The ORs (95% confidence intervals [95% CIs]) for an ACR70 response were 2.05 (95% CI 1.52\u20132.76) for adalimumab versus infliximab, 1.78 (95% CI 1.28\u20132.50) for etanercept versus infliximab, and 1.15 (95% CI 0.82\u20131.60) for adalimumab versus etanercept. Similar predictors and ORs were observed for a good response according to the European League Against Rheumatism criteria, DAS28 remission, and Clinical Disease Activity Index remission. At 48 months, the HRs for drug withdrawal were 1.98 for infliximab versus etanercept (95% 1.63\u20132.40), 1.35 for infliximab versus adalimumab (95% CI 1.15\u20131.58), and 1.47 for adalimumab versus etanercept (95% CI 1.20\u20131.80).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Older age, low functional status, and concomitant prednisolone treatment were negative predictors of a clinical response and remission. Infliximab had the lowest rates of treatment response, disease remission, and drug adherence, adalimumab had the highest rates of treatment response and disease remission, and etanercept had the longest drug survival rates. These findings were consistent after correction for confounders and sensitivity analyses and across outcome measures and followup times.<\/jats:p><\/jats:sec>","DOI":"10.1002\/art.27227","type":"journal-article","created":{"date-parts":[[2009,12,28]],"date-time":"2009-12-28T21:05:50Z","timestamp":1262034350000},"page":"22-32","source":"Crossref","is-referenced-by-count":456,"title":["Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: Results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry"],"prefix":"10.1002","volume":"62","author":[{"given":"Merete Lund","family":"Hetland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ib Jarle","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrik","family":"Tarp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lene","family":"Dreyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ib T\u00f8nder","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina","family":"Kollerup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Linde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanne M.","family":"Lindegaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uta Engling","family":"Poulsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Schlemmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorte Vendelbo","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Signe","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gisela","family":"Hostenkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikkel","family":"\u00d8Stergaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,12,28]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200011303432202"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)15640-7"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20217"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780390105"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.087262"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ken002"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kel149"},{"key":"e_1_2_8_9_2","first-page":"2398","article-title":"The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis","volume":"33","author":"Gartlehner G","year":"2006","journal-title":"J Rheumatol"},{"issue":"2","key":"e_1_2_8_10_2","doi-asserted-by":"crossref","first-page":"ii13","DOI":"10.1136\/ard.62.suppl_2.ii13","article-title":"Comparison of the efficacy of the tumor necrosis factor \u03b1 blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis","volume":"62","author":"Hochberg MC","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-148-2-200801150-00192"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-007-0475-6"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.083675"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.61.9.793"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.21570"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1185\/030079905X65510"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380602"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1186\/ar1740"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380107"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.22193"},{"issue":"5","key":"e_1_2_8_21_2","first-page":"S205","article-title":"DANBIO: a nationwide registry of biological therapies in Denmark","volume":"23","author":"Hetland ML","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_8_22_2","article-title":"An open source, self\u2010explanatory touch screen in the waiting room: validity of filling in the Bath measures on Ankylosing Spondylitis Disease Activity Index (BASDAI), Function Index (BASFI), the Health Assessment Questionnaire (HAQ) and Visual Analogue Scales in comparison with paper versions","author":"Schefte D","year":"2009","journal-title":"Rheumatology (Oxford)."},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1080\/03009740151095402"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kem075"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.031252"},{"key":"e_1_2_8_27_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.072447"},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.24463"},{"key":"e_1_2_8_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2006.06.011"},{"key":"e_1_2_8_30_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.031476"}],"container-title":["Arthritis &amp; Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.27227","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.27227","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,16]],"date-time":"2025-02-16T11:46:44Z","timestamp":1739706404000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/art.27227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12,28]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["10.1002\/art.27227"],"URL":"https:\/\/doi.org\/10.1002\/art.27227","archive":["Portico"],"relation":{},"ISSN":["0004-3591","1529-0131"],"issn-type":[{"value":"0004-3591","type":"print"},{"value":"1529-0131","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,12,28]]}}}